Experimental CAR-T therapy takes on Hard-to-Treat liver cancer
NCT ID NCT06757881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Researchers will watch for side effects like cytokine release syndrome and measure how long the cells last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL1RAP-targeting CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, tiny phase 1 trial with only 3 people, focused on safety, not effectiveness. The therapy may cause serious side effects like cytokine release syndrome, and it may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200000, China